RxDoctor Payments Data

Mary Middagh

Family · Helena, MTNPI 1396279709

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Sanofi at 41.4% of the total. 2025 is the largest year on record at $4,051, more than ten times the $43 reported in 2021. Among family clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,828in general payments, 2019–2025

Across 107 payments — averaging $54.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • AbbVie$813
  • Takeda Pharmaceuticals U.S.A., Inc.$488
  • Enterra Medical, Inc.$391
  • Johnson & Johnson$150
  • plus $385 from 10 others

What the payments were for

  • Consulting fees$95016%
  • Speaking & faculty fees$2,09636%
  • Food & beverage$2,68246%
  • Education$1002%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,828 in reported general payments places this provider in the 95th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$64,184
Medicare patients
214
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid14$132,155
Cimzia (2 Pack)Certolizumab Pegol13$72,941
CreonLipase/Protease/Amylase24$28,582
IbsrelaTenapanor Hcl12$21,086
TrulancePlecanatide14$8,629
MovantikNaloxegol Oxalate40$7,754
Budesonide DrBudesonide31$7,139
Lubiprostone30$5,323
Ursodiol19$4,843
Esomeprazole Magnesium36$1,622
Lidocaine Hcl ViscousLidocaine Hcl33$1,435
Omeprazole120$1,089
Pyridostigmine Bromide52$709
Pantoprazole Sodium31$556
Famotidine48$517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$813$28,58224 claims
Ardelyx, Inc.Ibsrela$15$21,08612 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$18$8,62914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 family providers in Montana.

Other family in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →